Relay Therapeutics Inc. Common Stock vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Relay Therapeutics Inc. Common Stock trades at $17.5 (market cap $3.94B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.62 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 18.3× Relay Therapeutics Inc. Common Stock's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Relay Therapeutics Inc. Common Stock for 0 Days and Vanguard Intermediate Term Corporate Bond ETF for 61 Days on average.
| RLAY | VCIT | |
|---|---|---|
Market Cap | $3.94B | $72.20B |
Volume | 3,432,928 | 14,162,206 |
Sector | Health | Fixed Income |
52-Week High | $20.75 | $84.82 |
52-Week Low | $6.03 | $77.98 |
Typical Hold Time | 0 Days | 61 Days |
Enterprise Value | $3.06B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VCIT trades at $78.27 with minimal daily movement (+0.04%). Technical indicators show a bearish trend with strong selling pressure in moving averages, though oscillators are neutral. The ETF offers a 4.8% yield with a 6-year duration, positioning it as a balanced income option among investment-grade corporate bond ETFs. Recent institutional buying includes Engineers Gate Manager LP's $1.27 million purchase in September 2026.
VCIT presents a compelling risk-return profile for income-focused investors seeking corporate bond exposure. The fund's low 0.03% expense ratio and higher yield compared to treasury alternatives provide value, though interest rate sensitivity and market volatility remain key risks. Analyst sentiment is generally positive given its competitive positioning in the fixed income ETF space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →